Epithelium

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Montag, April 15, 2024

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

Heidelberg Engineering Showcases the Future of Imaging, Extending Its Capabilities With a Breadth of Research Technology

Retrieved on: 
Dienstag, April 30, 2024

For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.

Key Points: 
  • For the first time, Heidelberg Engineering will demonstrate the future of digital imaging with its investigational SEELUMA, developed and manufactured by Heidelberg Engineering subsidiary, Munich Surgical Imaging and distributed exclusively by Bausch + Lomb.
  • The groundbreaking, fully digital, surgical-visualization platform features next-generation image technology with state-of-the-art intraoperative OCT that will transform the modern OR.
  • "In 2025, Heidelberg Engineering is set to revolutionize basic vision science with the introduction of the Heidelberg CHAMELEON Imaging Research Platform," said Heidelberg Engineering Clinical Development Manager — Investigational Technologies, Dr. Sebastian Rausch.
  • Monday night, Heidelberg Engineering will host an award presentation for the winner of the Heidelberg Engineering Xtreme Research Award that recognizes aspiring researchers for their outstanding contribution to ophthalmic research.

Novotech Publishes Analyst Report on Cystic Fibrosis Clinical Trial Landscape to Inform Biotech Research Planning 

Retrieved on: 
Donnerstag, April 11, 2024

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) --  Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report entitled Cystic Fibrosis - Global Clinical Trial Landscape.

Key Points: 
  • BOSTON, April 10, 2024 (GLOBE NEWSWIRE) --  Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released a comprehensive research report entitled Cystic Fibrosis - Global Clinical Trial Landscape.
  • The report presents a data-backed review of the Cystic Fibrosis (CF) funding landscape, trial density and patient recruitment data across geographies, standard of care and emerging therapies, recent USFDA approvals, and regulatory trends.
  • Importantly it also includes an in-depth SWOT analysis, to guide biotech firms on strategic decision-making, and research opportunities, and challenges.
  • The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Mittwoch, April 10, 2024

See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .

Key Points: 
  • See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
  • Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
  • Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Retrieved on: 
Montag, März 25, 2024

The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.

Key Points: 
  • The manuscript titled “ Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses ,” appears in the journal Clinical Cancer Research, one of oncology’s most prestigious journals.
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and tumors.
  • Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes.
  • Additionally, the changes in the tumor microenvironment we see in pancreatic cancer are similar to those we have seen in triple-negative breast cancer, ovarian cancer and colorectal cancer metastatic to the liver.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Montag, März 25, 2024

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

Society for Laboratory Automation and Screening (SLAS) Selects CytoTronics’ Pixel System for 2024 New Product Award

Retrieved on: 
Dienstag, März 5, 2024

CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).

Key Points: 
  • CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Award selection was announced at the SLAS2024 International Conference and Exhibition in Boston, MA on February 6th, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240305158077/en/
    CytoTronics' Pixel™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Front-runners are interviewed on-site at the conference by a panel of industry veterans with deep expertise in laboratory automation and screening techniques to determine final award recipients.

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Retrieved on: 
Montag, Februar 5, 2024

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.

Key Points: 
  • Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.
  • Pixel delivers simultaneous multi-modal, high-resolution readouts in 96- or 384-well plates, enabling cell monitoring and data collection at unprecedented scale.
  • It’s widely applicable for in vitro cell biology applications including drug discovery, from target validation to toxicology screening.”
    CytoTronics’ early-access program for Pixel Primo empowers cell biologists to unlock applications that were previously inaccessible.
  • The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

Retrieved on: 
Mittwoch, Januar 31, 2024

BNT325/DB-1305 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the trophoblast cell-surface antigen 2 (“TROP2”), a protein which is overexpressed on a range of tumor types.

Key Points: 
  • BNT325/DB-1305 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the trophoblast cell-surface antigen 2 (“TROP2”), a protein which is overexpressed on a range of tumor types.
  • The candidate is currently being evaluated in an ongoing Phase 1/2 study ( NCT05438329 ) in patients with TROP2-expressing advanced solid tumors.
  • Platinum-based chemotherapy is the backbone of treatment for ovarian epithelial cancer and related subtypes that form in the epithelial tissue.
  • “Recent studies have indicated the role of TROP2 in aggressive tumor growth and progression in patients with chemotherapy-resistant ovarian tumors.

Your fingerprint is actually 3D − research into holograms could improve forensic fingerprint analysis

Retrieved on: 
Mittwoch, Januar 17, 2024

But the imprint your finger leaves on the surface of the button is actually a 3D structure called a fingermark.

Key Points: 
  • But the imprint your finger leaves on the surface of the button is actually a 3D structure called a fingermark.
  • A 2D fingerprint neglects the depth of the fingermark, including pores and scars buried in the ridges of fingers that are difficult to see.
  • I’m an educator and scientist who studies holography, a field of research that focuses on how to display 3D information.

Fingermark types

  • Patent fingermarks are the most visible type – bloody fingerprints at crime scenes are one example.
  • Plastic fingermarks are found on soft surfaces, such as clay, Play-Doh or chocolate bars.
  • Cyanoacrylate makes super glue in its liquid form, but as a gas it can make latent fingermarks visible.


Finally, Level 3 features, such as pores, scars and creases, are too small for the human eye to resolve. This is where optical techniques like holography come in handy, since optical wavelengths are in the order of microns, small enough to make out small details on an object.

Developing fingermark holograms

  • Since fingermarks are usually collected as 2D pictures, and holograms display 3D information, my team wanted to develop a technique that can show all the 3D topological characteristics of a fingermark.
  • Columnar thin films are dense pillars of glassy material that uniformly cover the fingermark, like a dense growth of identical trees in a forest.
  • To make a hologram of something like a 3D fingermark, researchers split light from a laser into two parts.
  • One part, called the reference wave, shines directly on a digital camera.
  • The other wave shines on the object, in this case the fingermark.

Picking up fingermarks

  • In 2017, our collaboration reported our first results, where we made 3D pictures of latent fingermarks using the CTF technique.
  • We recorded holograms of the CTF-developed fingermarks with two different wavelengths of light – green and blue – generated from a laser.
  • The Miami Valley Regional Crime Lab in Dayton, Ohio, has graded the quality of the fingermarks captured by Lakhtakia’s research group.


Partha Banerjee’s Holography and Metamaterials (HaM) Lab has used Digital Holography for many applications funded by DARPA, Air Force and Army. The current joint work on fingermarks is supported by a grant from the Criminal Investigations and Network Analysis (CINA) Center of the Department of Homeland Security (DHS).